Diagnosis and treatment of atopic dermatitis

Jon Hanifin, Sai C. Chan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Atopic dermatitis is among the most common and highest-impact diseases of the skin. The prevalence appears to be increasing and corticosteroids remain the only available effective agents, despite their limitations and toxicity. Research is providing a better understanding of pathogenic factors in atopic dermatitis, opening new potential targets for therapeutic intervention. For severe disease, immune modulators such as cyclosporin A, methotrexate and IFN-γ are available as reasonable alternatives to the toxicity of systemic corticosteroids. New topical agents in the form of PDE4 inhibitors and FK506 are on the near horizon and should add some flexibility in approaching the management of this difficult disease.

Original languageEnglish (US)
Pages (from-to)9-18
Number of pages10
JournalDermatologic Therapy
Volume1
StatePublished - 1996
Externally publishedYes

Fingerprint

Atopic Dermatitis
Adrenal Cortex Hormones
Phosphodiesterase 4 Inhibitors
Tacrolimus
Disease Management
Skin Diseases
Methotrexate
Cyclosporine
Research
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Diagnosis and treatment of atopic dermatitis. / Hanifin, Jon; Chan, Sai C.

In: Dermatologic Therapy, Vol. 1, 1996, p. 9-18.

Research output: Contribution to journalArticle

@article{b073b003def444bba22a2b9882574db4,
title = "Diagnosis and treatment of atopic dermatitis",
abstract = "Atopic dermatitis is among the most common and highest-impact diseases of the skin. The prevalence appears to be increasing and corticosteroids remain the only available effective agents, despite their limitations and toxicity. Research is providing a better understanding of pathogenic factors in atopic dermatitis, opening new potential targets for therapeutic intervention. For severe disease, immune modulators such as cyclosporin A, methotrexate and IFN-γ are available as reasonable alternatives to the toxicity of systemic corticosteroids. New topical agents in the form of PDE4 inhibitors and FK506 are on the near horizon and should add some flexibility in approaching the management of this difficult disease.",
author = "Jon Hanifin and Chan, {Sai C.}",
year = "1996",
language = "English (US)",
volume = "1",
pages = "9--18",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Diagnosis and treatment of atopic dermatitis

AU - Hanifin, Jon

AU - Chan, Sai C.

PY - 1996

Y1 - 1996

N2 - Atopic dermatitis is among the most common and highest-impact diseases of the skin. The prevalence appears to be increasing and corticosteroids remain the only available effective agents, despite their limitations and toxicity. Research is providing a better understanding of pathogenic factors in atopic dermatitis, opening new potential targets for therapeutic intervention. For severe disease, immune modulators such as cyclosporin A, methotrexate and IFN-γ are available as reasonable alternatives to the toxicity of systemic corticosteroids. New topical agents in the form of PDE4 inhibitors and FK506 are on the near horizon and should add some flexibility in approaching the management of this difficult disease.

AB - Atopic dermatitis is among the most common and highest-impact diseases of the skin. The prevalence appears to be increasing and corticosteroids remain the only available effective agents, despite their limitations and toxicity. Research is providing a better understanding of pathogenic factors in atopic dermatitis, opening new potential targets for therapeutic intervention. For severe disease, immune modulators such as cyclosporin A, methotrexate and IFN-γ are available as reasonable alternatives to the toxicity of systemic corticosteroids. New topical agents in the form of PDE4 inhibitors and FK506 are on the near horizon and should add some flexibility in approaching the management of this difficult disease.

UR - http://www.scopus.com/inward/record.url?scp=0002055983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002055983&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0002055983

VL - 1

SP - 9

EP - 18

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

ER -